Outro raises $7M to scale supervised antidepressant tapering

CEO Brandon Goode says a gap he saw in psychedelic care led him to build an off-ramp for patients struggling to stop long-term medication.

By · Published

Outro raises $7M to scale supervised antidepressant tapering — CEO Brandon Goode says a gap he saw in psychedelic care led him to build an off-ramp for patients struggling to stop long-term medication.

CEO Brandon Goode says a gap he saw in psychedelic care led him to build an off-ramp for patients struggling to stop long-term medication.